ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2013
Significant improvement in survival after allogeneic hematopoietic cell transplantation during a period of significantly increased use, older recipient age, and use of unrelated donors.
Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 131 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
131 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Research Methodology and Study Design Working Group Report.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2017Guideline
- Indications for Autologous and Allogeneic Hematopoietic Cell Transplantation: Guidelines from the American Society for Blood and Marrow Transplantation.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2015Guideline
- Randomized Controlled Trial of a Virtually Delivered Exercise and Stress Management Program to Improve Physical Performance of Hematopoietic Cell Transplant Survivors.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025Trial
- Social support as a moderator of healthcare adherence and distress in long-term hematopoietic cell transplantation survivors.Journal of cancer survivorship : research and practice · 2021Trial
- An evidence-based stress management intervention for allogeneic hematopoietic stem cell transplant caregivers: development, feasibility and acceptability.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2017Trial
- Pre-existing invasive fungal infection is not a contraindication for allogeneic HSCT for patients with hematologic malignancies: a CIBMTR study.Bone marrow transplantation · 2017Trial
- Phase I/II Trial of Dose-Escalated Busulfan Delivered by Prolonged Continuous Infusion in Allogeneic Transplant Patients.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2015Trial
- Allogeneic hematopoietic stem cell transplantation after azacitidine and venetoclax salvage in relapsed/refractory AML: a multicenter real-world study by the French AURAML group.Bone marrow transplantation · 2026Observational
- Factors Associated with Receipt of Allogeneic Hematopoietic Cell Transplant and NMDP Donor Search in Older Adults with Acute Myeloid Leukemia.Transplantation and cellular therapy · 2026Article
- Donor type and post-transplant outcomes in anti-thymocyte globulin based allogeneic transplantation for myelodysplastic syndromes.Annals of hematology · 2026Article
- Has early mortality following single-unit unrelated cord blood transplantation improved in recent years? A nationwide registry data analysis from 2003 to 2022 in Japan.British journal of haematology · 2025Article
- DecodingAcute GVHD: The role of serum biomarkers and imaging in diagnosis and management.Blood reviews · 2025Review
- Young unrelated donors confer a survival advantage for patients with myeloid malignancies compared to older siblings.Leukemia · 2025Article
- Glutamic acid decarboxylase antibody-spectrum disorders and type 1 diabetes mellitus in a patient following allogenic hematopoietic cell transplantation with review of literature.Endocrine journal · 2025Review
- Complement activation and vascular complications after pediatric allogeneic hematopoietic stem cell transplantation.Scientific reports · 2025Article
- Allogeneic hematopoietic cell transplantation from alternative donors in acute myeloid leukemia.Annals of hematology · 2024Review
- Article
- Use of Hematopoietic Cell Transplant for Hematologic Cancers by Race, Ethnicity, and Age.JAMA network open · 2024Article
- Trends in volumes and survival after hematopoietic cell transplantation in racial/ethnic minorities.Blood advances · 2024Observational
- Cord blood transplantation for adult mature lymphoid neoplasms in Europe and Japan.Blood advances · 2024Article
71 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
16 authors.
Funding
Abstract
purposeOver the past four decades, allogeneic hematopoietic cell transplantation (alloHCT) has evolved as a curative modality for patients with hematologic diseases. This study describes changes in use, technique, and survival in a population-based cohort. PATIENTS AND
methodsThe study included 38,060 patients with hematologic malignancies or disorders who underwent first alloHCT in a US or Canadian center from 1994 to 2005 and were reported to the Center for International Blood and Marrow Transplant Research.
resultsAlloHCT as treatment for acute lymphoblastic (ALL) and myeloid leukemias (AML), myelodysplastic syndrome (MDS), and Hodgkin and non-Hodgkin lymphomas increased by 45%, from 2,520 to 3,668 patients annually. From 1994 to 2005, use of both peripheral (7% to 63%) [corrected] and cord blood increased (2% to 10%), whereas use of marrow decreased (90% to 27%). Despite a median age increase from 33 to 40 years and 165% [corrected] increase in unrelated donors for alloHCT, overall survival (OS) at day 100 significantly improved for patients with AML in first complete remission after myeloablative sibling alloHCT (85% to 94%; P < .001) and unrelated alloHCT (63% to 86%; P < .001); 1-year OS improved among those undergoing unrelated alloHCT (48% to 63%; P = .003) but not among those undergoing sibling alloHCT. Similar results were seen for ALL and MDS. Day-100 OS after cord blood alloHCT improved significantly from 60% to 78% (P < .001) for AML, ALL, MDS, and chronic myeloid leukemia. Use of reduced-intensity regimens increased, yielding OS rates similar to those of myeloablative regimens.
conclusionSurvival for those undergoing alloHCT has significantly improved over time. However, new approaches are needed to further improve 1-year OS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.